ClinicalTrials.gg
CompletedNCT06417229Updated Mar 6, 2025

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

A Phase 1 interventional study of BMS-986365 and Rabeprazole in Healthy Participants, sponsored by Celgene. Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, drug levels, food effects and relative bioavailability of BMS-986365 in healthy male participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • BMS-986365
  • Pharmacokinetics
  • Relative Bioavailability
  • Healthy Male Volunteers
  • CC-94676
  • Food Effect
  • Proton Pump Inhibitor
03

In context

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted after Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult male participants as determined by no deviations from normal in medical history, physical examination, vital signs, ECGs, echocardiogram, or clinical laboratory assessments as determined by the investigator.
  • (BMI) of 18.0 to 32.0 kg/m\^2, inclusive.

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic illness.
  • Prior history of heart failure, ischemic heart diseases, serious cardiac arrythmias, or prolonged .
  • History of allergy/ to any component (including ) of BMS-986365 study interventions or related compounds.
  • Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Part 1: Cohort 1 BMS-986365 Dose 1

    Drug: BMS-986365

  • Experimental
    Part 1: Cohort 2 BMS-986365 Dose 2 Formulation 1

    Drug: BMS-986365

  • Experimental
    Part 1: Cohort 2 BMS-986365 Dose 3 Formulation 2

    Drug: BMS-986365

  • Experimental
    Part 1: Cohort 3 BMS-986365 Dose 4

    Drug: BMS-986365

  • Experimental
    Part 1: Cohort 6 BMS-986365 Dose 5

    Drug: BMS-986365

  • Experimental
    Part 1: Cohort 7 BMS-986365 Dose 6

    Drug: BMS-986365

  • Experimental
    Part 1: Cohort 8 BMS-986365 Dose 7

    Drug: BMS-986365

  • Experimental
    Part 1: Cohort 9 BMS-986365 Dose 8

    Drug: BMS-986365

  • Experimental
    Part 2: Cohort 4 BMS-986365 Dose 9 Fasted

    Drug: BMS-986365

  • Experimental
    Part 2: Cohort 4 BMS-986365 Dose 10 Fed

    Drug: BMS-986365

  • Experimental
    Part 2: Cohort 5 BMS-986365 Dose 11 Fasted Followed by Rabeprazole + Rabeprazole and BMS-986365

    Drug: BMS-986365 · Drug: Rabeprazole

Interventions

  • Specified dose on specified days

    Also known as: CC-94676

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to Day 75

  2. Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)]

    Time frame: Up to Day 75

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]

    Time frame: Up to Day 75

Secondary outcomes

  1. To assess the bioavailability of BMS-986365 experimental formulation relative to the reference formulation

    Time frame: Up to Day 75

  2. Incidence of adverse events (AE)

    Time frame: Up to Day 75

  3. Incidence of serious adverse events (SAE)

    Time frame: Up to Day 75

  4. Number of participants with physical examination abnormalities

    Time frame: Up to Day 75

  5. Number of participants with vital sign abnormalities

    Time frame: Up to Day 75

  6. Number of participants with clinical laboratory abnormalities

    Time frame: Up to Day 75

  7. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to Day 75

07

Study locations

1 site
  • Local Institution - 0001
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and research/disclosurecommitment.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Feb 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2024
First posted
May 16, 2024
StartActual
May 28, 2024
Primary completionActual
Feb 19, 2025
CompletionActual
Feb 19, 2025
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06417229
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
May 16, 2024
Start date
May 28, 2024
Primary completion
Feb 19, 2025
Completion
Feb 19, 2025
Last update
Mar 6, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dezandrodeg

Start the discussion